Trial Profile
An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms GALAXY
- Sponsors Bayer
- 24 Dec 2018 Status changed from active, no longer recruiting to completed.
- 23 Nov 2018 Planned End Date changed from 31 Oct 2018 to 30 Nov 2018.
- 23 Nov 2018 Planned primary completion date changed from 31 Oct 2018 to 30 Nov 2018.